Isabella Ciccone, MPH

Minoryx's leriglitazone showed a decrease in matrix metalloproteinase-9 concentrations in pediatric patients with cerebral adrenoleukodystrophy, according to a 24-week analysis.

The wearable device received its original FDA go-ahead in 2019, and has since demonstrated effectiveness in preventive and acute care for migraine treatment in adolescents and adults.

Researchers designed a new screening tool to assist nonmovement disorders specialists with identifying involuntary movements in patients aged at least 4 years of age with an inborn error of metabolism.